by Oleg Vishnevski | Sep 30, 2020 | News, Products
Testosterone Administration During Energy Deficit Suppresses Hepcidin and Increases Iron Availability for Erythropoiesis Context: Severe energy deprivation markedly inhibits erythropoiesis by restricting iron availability for hemoglobin synthesis. Objective:...
by Oleg Vishnevski | Sep 24, 2020 | News, Products
Role of Hepcidin to Identify the Type of Anemia in Chronic Kidney Disease in Children See full study: https://iopscience.iop.org/article/10.1088/1742-6596/1246/1/012023/meta Abstract Chronic kidney disease (CKD) may present with anemia of chronic disease (ACD),...
by Oleg Vishnevski | May 1, 2020 | Products
Can hepcidin be a useful marker in the diagnosis and monitoring of De Quervain thyroiditis? Endocrine Abstracts (2019) 63 GP182 | DOI: 10.1530/endoabs.63.GP182Dorota Filipowicz, Aleksandra Hernik, Ewelina Szczepanek-Parulska & Marek Ruchała Author affiliations...
by Oleg Vishnevski | Jul 28, 2016 | Products
Unique Assay For DRG:HYBRID-XL®: Hepcidin 25 (Bioactive) DRG is proud to announce that Hepcidin 25 (bioactive) is now available for DRG:HYBRiD-XL. The new assay include 40 tests and has an incubation time of 120 min in total. Serum or plasma samples can be run with...
by Oleg Vishnevski | Jul 28, 2016 | Products
Two New Assays For DRG:HYBRID-XL® DRG is expanding the Fertility panel with LH and Prolactin! DRG is proud to launch two parameters: LH and Prolactin are now available for our lab analyzer DRG:HYBRiD-XL®. Both new assays have an incubation time of 90 min in total....
by Oleg Vishnevski | Sep 24, 2014 | Products
Cystatin C: New Clinical Chemistry Parameter Available For DRG:HYBRiD-XL DRG is glad to announce the next release of a clinical chemistry assay. Cystatin C is the latest released parameter for DRG:HYBRiD-XL and is ready to be purchased! Cystatin C: New clinical...
